### **Overview** Apollo Hospitals Enterprise Limited (AHEL) is India’s largest and most integrated private healthcare provider, with over four decades of clinical excellence and innovation since its inception in 1983. Operating across hospitals, clinics, diagnostics, digital health, pharmacy, and home care, AHEL has evolved into a pan-India and increasingly global healthcare ecosystem. The company is driving a transformation in healthcare delivery by combining deep clinical expertise with cutting-edge technology, omnichannel accessibility, and patient-centric care models. --- ### **Strategic Focus Areas (2025)** #### **1. Integrated Healthcare Ecosystem ("One Apollo")** Apollo has established a cohesive, end-to-end care continuum through its multi-platform approach: - **Hospitals & Specialty Care:** 71 hospitals across India, with 9,463 beds (as of Q1 FY26), expanding to approximately 13,000 beds over the next five years. - **Retail & Ambulatory Care:** Apollo Health and Lifestyle Limited (AHLL), a subsidiary, manages over 3,071 retail healthcare centers under brands such as Apollo Clinics, Apollo Cradle, Apollo Spectra, Apollo Dental, and Apollo Dialysis. - **Digital Health:** Apollo 24/7 serves as the digital backbone, integrating teleconsultations, e-pharmacy, diagnostics, insurance, and electronic health records into a 360-degree platform. - **Home Health & Telehealth:** Extensive home care services and India’s largest telemedicine network (ATHS) with more than 700 teleclinics and 24/7 emergency support (1066 helpline). --- ### **Growth Drivers (2025 Insights)** #### **A. Expansion of Bed Capacity & Geographic Footprint** - **Near-Term Expansion (2025–2026):** - Adding **840 new beds** through: - 500 beds (greenfield) at Sarjapur-2, Bengaluru. - 200 beds via acquisition in Sarjapur-1, Bengaluru. - 140 beds from expansions in Malleswaram and Mysore. - Post-expansion, total beds in **Bengaluru will reach 1,500**. - **Long-Term Plans (Next 5 years):** - Add **4,300 beds** via greenfield, brownfield, and acquisitions at an estimated capex of ₹8,000+ crores. - Key projects include 600-bed greenfield hospital on OMR, Chennai and new facilities in Pune, Kolkata, Gurgaon, and Delhi NCR. #### **B. Oncology as a Strategic Growth Vertical** - Focused presence in **five major markets**: Chennai, Mumbai, Bengaluru, Hyderabad, and NCR. - Integrated **pan-India oncology program** combining precision medicine, global protocols, and multidisciplinary care. - Aims to **double oncology revenue to over ₹5,000 crore in 3–4 years** via: - Expansion of Apollo Proton Cancer Centre (Chennai), the only facility of its kind in Southeast Asia. - Adoption of **CAR T-cell therapy** for refractory leukemias and lymphomas. - Launch of AI-powered **precision oncology center** in Bengaluru. #### **C. Digital & Omni-channel Integration** - **Apollo 24/7:** - Over **41 million registered users** (up from 34 million in June 2024). - Daily active users: **795,275**. - Services include: - 13,000+ daily medicine orders. - 57,000+ sample collections. - 2,500+ virtual consultations per day. - 19-minute medicine delivery in multiple cities. - **Clinical Intelligence Engine (CIE):** - India’s first AI-driven Clinical Intelligence Engine. - Powered by 80+ million patient records and 500+ specialist validations. - Triages symptoms, recommends diagnostics, and guides care paths for over 1,200 conditions. #### **D. Diagnostics & Primary Care Expansion** - **Diagnostic Infrastructure:** - New **45,000 sq. ft. Digi-Smart Central Lab** in Chennai (daily capacity: ~100,000 samples). - Combined capacity with Hyderabad lab: **150,000 samples/day**. - Added 5 satellite labs and 65 collection centers in Q1 FY26. - Wellness segment accounts for **20% of diagnostics revenue** (up from 18% in FY24). - **Primary Care Growth:** - Targeting **high-teen CAGR** in Primary Care & Diagnostics. - Investing in **next-gen testing** (genomics, personalized screenings). - Rebranding and tech upgrades across **Apollo Diagnostics** and **Global Reference Labs**. #### **E. Apollo Pharmacies & Pharmacy Ecosystem** - **Physical Network:** - **6,742 stores** across ~1,200 cities in 22 states and 5 UTs (as of Aug 2025). - Serves **~880,000 customers daily**. - **Private & Generic Labels:** - Represent **15.8% of offline sales** (Q1 FY26). - Focus on higher-margin private label portfolio. - **Omni-channel GMV:** - **INR 682 crore GMV** in Q1 FY26 (+23% YoY). - Full-year FY25 GMV: **INR 3,077 crore**. --- ### **Corporate Restructuring & Strategic Alliances** #### **1. Apollo HealthCo & Keimed Merger** - **Objective:** Create **India’s largest listed omni-channel pharmacy (OCP) and digital health platform**. - **Key Steps:** - AHEL raised **INR 2,475 crore ($300 million)** from **Advent International** in two tranches (Sep 2024, Mar 2025). - **Acquisition of 11.2% stake** in **Keimed**, India’s largest wholesale pharmaceutical distributor. - **Composite scheme** to merge Keimed into Apollo HealthCo via demerger of Apollo 24/7, digital platform, and telehealth units into a new entity (“NewCo”). - **Projected Outcomes:** - Combined entity to generate **~INR 16,300 crore (~$1.9B) in FY25 revenue**. - Target run-rate of **INR 25,000 crore (~$3B) by end-FY27**. - Expected **EBITDA margin of ~7%**, with significant cost synergies and supply chain optimization. - **Full ownership expected**, enabling direct stakeholder ownership in the digital and pharmacy vertical. #### **2. Acquisition of AHLL Stake** - **INR 1,254 crore** investment to acquire the remaining **31% stake** in **Apollo Health and Lifestyle Limited (AHLL)**. - AHLL to become **99.42% subsidiary** of AHEL. - Strategic Benefits: - Improved **capital allocation**, **ROCE**, and **operational synergies**. - Focus on four dedicated ambulatory verticals: 1. Primary Care & Diagnostics 2. Birthing & Women's Health 3. Ambulatory Care (short-stay & urgent care) 4. Dialysis & Dental Networks --- ### **Retail & Consumer Health Initiatives (2025)** - **Consumerization of Healthcare:** - Shifting from hospital-led care to **community-based care delivery**. - AHLL’s **hub-and-spoke model** connects retail clinics to tertiary hospitals, enabling internal referrals and seamless care. - **Vertical-Specific Expansions:** - **Apollo Cradle:** Strengthening leadership in maternal, fertility, and pediatric care. Achieved ~9% YoY revenue growth; new center planned for Q3 FY26. - **Apollo Fertility:** ~11% revenue growth; launched new knowledge center. - **Apollo Dental:** Introduced **Straumann implant system**; expanding via SIS-hospital (shop-in-shop) model. - **Dialysis & Dental:** Scaling independently via partnerships to meet unmet demand, driven by 15% CAGR in dialysis market. --- ### **Technology & Innovation (2025)** - **AI & Robotics:** - Deploying **AI-CVD risk prediction**, **AI in radiology**, and **smart in-patient automation**. - Over **1,000 robotic colorectal surgeries** performed—India’s highest volume. - Robotic knee replacement performed on **17-year-old**, world’s youngest case. - **Advanced Therapies:** - **ZaP-X Gyroscopic Radiosurgery** — Non-invasive brain tumor treatment. - **CyberKnife S7** with AI-Synchrony® for motion tracking in radiotherapy. - **Vita Smart HOPE** device for improved kidney transplantation success. - **Digitization:** - Paperless hospitals, EMR-integrated workflows, and real-time analytics. --- ### **Market Position & Competitive Advantages** - **Scale & Integration:** - Only integrated ecosystem covering **hospitals, clinics, digital, diagnostics, pharmacy, home, and international care**. - **Largest pharmacy network**, **leading telehealth platform**, and **top employer of medical talent**. - **Brand Trust:** - Most trusted healthcare brand in India. - Attracts medical value travelers from **120+ countries**. - Key player in **"Heal in India" initiative**. - **Operational Excellence:** - Achieved **31% ROCE in FY24**. - Digital platforms reached **EBITDA breakeven faster than peers**. - Strong **customer lifetime value (LTV)** and **low customer acquisition cost (CAC)**.